Alkem Labs Daman facility gets OAI status from US FDA after inspection

Regulatory & Legal View source PDF Explain this filing

ALKEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.6%Reaction day

₹5597.50

prior close

₹5520.50

announcement price

After-mkt

timing

Nifty Midcap 150market+0.2%+0.4% vs market

Pharmaceuticals peers, median of 167sector+0.3%+0.4% vs sector

On the reaction day the stock moved 0.4 pts more than Nifty Midcap 150 and 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.6

10m

+1.4

15m

+1.3

30m

+1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.6+0.2+0.4+0.3+0.4

Next day

+0.0+0.7-0.7+0.7-0.7

-1.6+0.6-2.2+0.6-2.2

-2.6+0.9-3.5+0.5-3.1

-2.6+1.0-3.6+1.2-3.9

-4.1+0.5-4.6+0.2-4.3

-2.2+0.2-2.4+0.2-2.4

15d

-3.7+0.8-4.6+1.4-5.1

-7.9-1.1-6.8+2.4-10.3

-4.1-6.3+2.2+1.8-5.9

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

US FDA has classified Alkem Labs' Amaliya, Daman manufacturing facility as Official Action Indicated (OAI), following an inspection from April 20 to May 1, 2026 that resulted in a Form 483 with seven observations. The company says it will continue manufacturing and supplying approved products from this facility to the US market and will work with the regulator to achieve fully compliant status.

Likely market impact

Negative: OAI status may delay new US product approvals from this plant and could pressure export revenue going forward.